BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

Rhea-AI Summary

BioSig Technologies (NASDAQ: BSGM) has announced the pricing of its public offering of 3,852,149 shares of common stock at $3.90 per share. The offering, expected to close around August 15, 2025, aims to raise gross proceeds of approximately $15.02 million.

The company plans to use the net proceeds to purchase gold bullion according to its investment policy, along with working capital and general corporate purposes. Clear Street and Needham & Company are serving as joint book-running managers for this offering, which is being conducted under an effective S-3 shelf registration.

Positive

• Raising $15.02 million in gross proceeds to strengthen balance sheet
• Successful pricing of offering indicates market interest
• Strategic investment in gold bullion diversifies company assets

Negative

• Potential dilution for existing shareholders with 3.85 million new shares
• Share offering priced at $3.90 may pressure current stock price

Insights

Financial Analyst

BioSig's $15M offering dilutes shares by 5.6% while building gold reserves, indicating defensive positioning amid uncertain market conditions.

BioSig's $15 million public offering represents a notable capital raise for the recently merged entity. At $3.90 per share, the company is issuing 3,852,149 new shares, which will create dilution for existing shareholders. Based on the pricing, we can calculate an implied post-offering valuation of approximately $267 million assuming this represents roughly 5.6% of total outstanding shares after the offering.

What's particularly interesting is the stated use of proceeds - to purchase gold bullion. This is an unusual allocation strategy for a technology company and signals the management's defensive positioning. Rather than investing primarily in R&D, operations expansion, or acquisition activities typical of growth-stage companies, BioSig is allocating capital toward a traditional safe-haven asset.

The gold bullion strategy likely stems from the Streamex merger, as cryptocurrency exchanges often maintain significant asset reserves. This approach could be intended to provide balance sheet stability during uncertain market conditions or potentially hedge against inflation. However, it also raises questions about the company's confidence in organic growth opportunities within its core business.

The joint management of the offering by Clear Street and Needham & Company lends credibility to the transaction, though investors should note the inevitable dilution effect on earnings per share. The scheduled closing within two days suggests institutional interest was sufficient to complete the transaction quickly, which is a moderately positive signal amid challenging market conditions for public offerings.

Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.

Clear Street and Needham & Company are acting as joint book-running managers of the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-276298) declared effective by the Securities and Exchange Commission (the “SEC”) on December 17, 2024. A final prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission, together with an accompanying base prospectus. The securities may be offered only by means of a written prospectus forming a part of the effective registration statement. Copies of the final prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained, when available from the SEC’s website at http://www.sec.gov, from Clear Street, Attention: Syndicate, 4 World Trade Center, 150 Greenwich St, Floor 46, New York, NY 10007, or by email at syndicate@clearstreet.io and Needham & Company, 250 Park Avenue, 10th Floor, New York, NY 10177, Attn: Prospectus Department, prospectus@needhamco.com or by telephone at (800) 903-3268.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. BioSig will not, and has been advised by the joint book-running managers that they and their affiliates will not, sell any of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Streamex

Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and an institutional grade tokenization platform.  Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

About BioSig Technologies

BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.

The PURE EP™ Platform enables electrophysiologists to acquire raw signal data in real-time—absent of unnecessary noise or interference—to maximize procedural success and minimize unnecessary inefficiencies. As physician advocates, we believe that the ability to maintain the integrity of intracardiac signals with precision and clarity without driving up procedural costs has never been more pertinent.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition and recently announced convertible debenture financing and standby equity purchase agreement will be obtained, and whether we will be able to maintain compliance with Nasdaq’s listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

Press & Investor Relations:

Ele Kauderer

PR@PhoenixMGMTconsulting.com

+1 888-228-0122

Henry McPhie

CEO of BioSig, Co-Founder of Streamex
contact@Streamex.com
https://x.com/streamex

FAQ

What is the size and price of BioSig Technologies (BSGM) August 2025 public offering?

BioSig is offering 3,852,149 shares of common stock priced at $3.90 per share, aiming to raise approximately $15.02 million in gross proceeds.

How will BioSig (BSGM) use the proceeds from its 2025 public offering?

BioSig plans to use the net proceeds to purchase gold bullion in accordance with its investment policy, for working capital, and for general corporate purposes.

When will BioSig's (BSGM) public offering close?

The offering is expected to close on or around August 15, 2025, subject to customary closing conditions.

Who are the underwriters for BioSig's (BSGM) 2025 public offering?

Clear Street and Needham & Company are acting as joint book-running managers for the offering.

What is the registration status of BioSig's (BSGM) public offering?

The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276298) declared effective by the SEC on December 17, 2024.